Please ensure Javascript is enabled for purposes of website accessibility

Why Lineage Cell Therapeutics Stock Is Soaring Today

By Keith Speights - Updated Jun 1, 2021 at 12:12PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company reported great news from a clinical study of its experimental cell therapy for treating eye disease.

What happened

Shares of Lineage Cell Therapeutics (LCTX -1.36%) were soaring by 19.4% as of 12:01 p.m. EDT on Tuesday. The big gain came after the company announced positive news from a phase 1/2a study evaluating OpRegen in treating dry age-related macular degeneration (AMD).

So what 

Lineage Cell Therapeutics reported it observed restoration of retinal tissue in two additional patients in its study of OpRegen. The company reported its first case of retinal restoration last year. CEO Brian Culley said, "To our knowledge, these three patients represent the only examples of an experimental treatment for dry AMD demonstrating a reduction, rather than attenuating further expansion, of an area of atrophy in humans."

Letters spelling AMD next to a plastic eyeball with an eye chart in the background.

Image source: Getty Images.

The news is so encouraging that Lineage filed a Patent Cooperation Treaty (PCT) patent application for the restoration of the anatomy and/or functionality of diseased retinas. This filing enables the company to seek patent protection in multiple countries simultaneously. If Lineage receives approval for its patent application, it would have intellectual property protection at least through May 24, 2041.

Now what

Lineage now plans to discuss its detailed findings from the study of OpRegen with external therapeutic experts. The company also will evaluate its pathways for regulatory approval of the allogeneic retinal pigment epithelium (RPE) cell transplant therapy. With three of four patients who received OpRegen so far experiencing retinal tissue restoration, the prospects for this biotech stock appear bright.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Lineage Cell Therapeutics, Inc. Stock Quote
Lineage Cell Therapeutics, Inc.
$1.45 (-1.36%) $0.02

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/19/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.